Eiko Lifesciences Share Price
Sector: Chemical Manufacturing
50.00 -2.09 (-4.01%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
47.10
Today’s High
52.50
52 Week Low
42
52 Week High
74.88
Key Metrics
- Market Cap (In Cr) 62.1
- Beta -0.01
- Div. Yield (%) 0
- P/B 1.26
- TTM P/E 36.07
- Peg Ratio 1.31
- Sector P/E 0
- D/E 0
- Open Price 51.93
- Prev Close 52.09
Eiko Lifesciences Analysis
Price Analysis
-
1 Week3.27%
-
3 Months-4.4%
-
6 Month-13.73%
-
YTD-16.97%
-
1 Year2.97%
Risk Meter
- 55% Low risk
- 55% Moderate risk
- 55% Balanced Risk
- 55% High risk
- 55% Extreme risk
Eiko Lifesciences News
Q4 results today: Tata Power, Eicher Motors, Lupin, Shree Cements on May 14
1 min read . 14 May 2025Q4 results today: Varun Beverages, Zomato & Sanofi to report earnings on May 13
1 min read . 13 May 2024Eiko Lifesciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 37.66
- Selling/ General/ Admin Expenses Total
- 0.37
- Depreciation/ Amortization
- 0.74
- Other Operating Expenses Total
- 1.88
- Total Operating Expense
- 35.3
- Operating Income
- 2.36
- Net Income Before Taxes
- 3.06
- Net Income
- 2.32
- Diluted Normalized EPS
- 1.44
- Period
- 2025
- Total Assets
- 66.1
- Total Liabilities
- 9.31
- Total Equity
- 56.79
- Tangible Book Valueper Share Common Eq
- 41.26
- Period
- 2025
- Cashfrom Operating Activities
- 2.92
- Cashfrom Investing Activities
- -11.44
- Cashfrom Financing Activities
- 6.96
- Net Changein Cash
- -1.57
- Period
- 2024
- Total Revenue
- 27.93
- Selling/ General/ Admin Expenses Total
- 0.22
- Depreciation/ Amortization
- 0.66
- Other Operating Expenses Total
- 0.68
- Total Operating Expense
- 26.98
- Operating Income
- 0.95
- Net Income Before Taxes
- 0.98
- Net Income
- 0.75
- Diluted Normalized EPS
- 0.73
- Period
- 2024
- Total Assets
- 52.74
- Total Liabilities
- 2.06
- Total Equity
- 50.68
- Tangible Book Valueper Share Common Eq
- 36.56
- Period
- 2024
- Cashfrom Operating Activities
- -7.08
- Cashfrom Investing Activities
- -0.55
- Cashfrom Financing Activities
- 20.36
- Net Changein Cash
- 12.73
- Period
- 2023
- Total Revenue
- 18.32
- Selling/ General/ Admin Expenses Total
- 0.29
- Depreciation/ Amortization
- 0.63
- Other Operating Expenses Total
- 0.99
- Total Operating Expense
- 18
- Operating Income
- 0.32
- Net Income Before Taxes
- 1.03
- Net Income
- 0.77
- Diluted Normalized EPS
- 0.8
- Period
- 2023
- Total Assets
- 31.04
- Total Liabilities
- 1.62
- Total Equity
- 29.42
- Tangible Book Valueper Share Common Eq
- 30.66
- Period
- 2023
- Cashfrom Operating Activities
- 4.22
- Cashfrom Investing Activities
- 2
- Cashfrom Financing Activities
- -4.7
- Net Changein Cash
- 1.52
- Period
- 2022
- Total Revenue
- 25.41
- Selling/ General/ Admin Expenses Total
- 0.28
- Depreciation/ Amortization
- 0.56
- Other Operating Expenses Total
- 1.26
- Total Operating Expense
- 24.68
- Operating Income
- 0.73
- Net Income Before Taxes
- 0.94
- Net Income
- 0.71
- Diluted Normalized EPS
- 0.78
- Period
- 2022
- Total Assets
- 34.89
- Total Liabilities
- 6.26
- Total Equity
- 28.63
- Tangible Book Valueper Share Common Eq
- 29.83
- Period
- 2022
- Cashfrom Operating Activities
- -7.73
- Cashfrom Investing Activities
- 0.59
- Cashfrom Financing Activities
- 3.28
- Net Changein Cash
- -3.85
- Period
- 2021
- Total Revenue
- 11.99
- Selling/ General/ Admin Expenses Total
- 0.12
- Depreciation/ Amortization
- 0.06
- Other Operating Expenses Total
- 0.74
- Total Operating Expense
- 11.53
- Operating Income
- 0.46
- Net Income Before Taxes
- 0.83
- Net Income
- 0.61
- Diluted Normalized EPS
- 1.39
- Period
- 2021
- Total Assets
- 16.61
- Total Liabilities
- 4.09
- Total Equity
- 12.53
- Tangible Book Valueper Share Common Eq
- 28.42
- Period
- 2021
- Cashfrom Operating Activities
- -0.83
- Cashfrom Investing Activities
- -2.94
- Cashfrom Financing Activities
- 7.81
- Net Changein Cash
- 4.05
- Period
- 2020
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.07
- Depreciation/ Amortization
- 0.06
- Other Operating Expenses Total
- 0.1
- Total Operating Expense
- 0.23
- Operating Income
- -0.23
- Net Income Before Taxes
- 0.13
- Net Income
- 0.13
- Diluted Normalized EPS
- 0.29
- Period
- 2020
- Total Assets
- 5.76
- Total Liabilities
- 0.28
- Total Equity
- 5.48
- Tangible Book Valueper Share Common Eq
- 12.44
- Period
- 2020
- Cashfrom Operating Activities
- 0.77
- Cashfrom Investing Activities
- -0.65
- Cashfrom Financing Activities
- -0.13
- Net Changein Cash
- -0.01
- Period
- 2025-03-31
- Total Revenue
- 11.27
- Selling/ General/ Admin Expenses Total
- 0.11
- Depreciation/ Amortization
- 0.25
- Other Operating Expenses Total
- 0.73
- Total Operating Expense
- 9.87
- Operating Income
- 1.4
- Net Income Before Taxes
- 1.64
- Net Income
- 1.24
- Diluted Normalized EPS
- 0.63
- Period
- 2025-03-31
- Total Assets
- 66.1
- Total Liabilities
- 9.31
- Total Equity
- 56.79
- Tangible Book Valueper Share Common Eq
- 41.26
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 2.92
- Cashfrom Investing Activities
- -11.44
- Cashfrom Financing Activities
- 6.96
- Net Changein Cash
- -1.57
- Period
- 2024-12-31
- Total Revenue
- 6.91
- Selling/ General/ Admin Expenses Total
- 0.11
- Depreciation/ Amortization
- 0.15
- Other Operating Expenses Total
- 0.25
- Total Operating Expense
- 6.61
- Operating Income
- 0.3
- Net Income Before Taxes
- 0.38
- Net Income
- 0.29
- Diluted Normalized EPS
- 0.22
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 7.74
- Selling/ General/ Admin Expenses Total
- 0.06
- Depreciation/ Amortization
- 0.16
- Other Operating Expenses Total
- 0.38
- Total Operating Expense
- 7.55
- Operating Income
- 0.19
- Net Income Before Taxes
- 0.28
- Net Income
- 0.21
- Diluted Normalized EPS
- 0.16
- Period
- 2024-09-30
- Total Assets
- 54.78
- Total Liabilities
- 3.55
- Total Equity
- 51.23
- Tangible Book Valueper Share Common Eq
- 36.96
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -4.06
- Cashfrom Investing Activities
- -6.52
- Cashfrom Financing Activities
- 0.36
- Net Changein Cash
- -10.22
- Period
- 2024-06-30
- Total Revenue
- 10.75
- Selling/ General/ Admin Expenses Total
- 0.13
- Depreciation/ Amortization
- 0.17
- Other Operating Expenses Total
- 0.31
- Total Operating Expense
- 10.52
- Operating Income
- 0.23
- Net Income Before Taxes
- 0.46
- Net Income
- 0.35
- Diluted Normalized EPS
- 0.27
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 8.4
- Selling/ General/ Admin Expenses Total
- 0.05
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 0.08
- Total Operating Expense
- 8.06
- Operating Income
- 0.34
- Net Income Before Taxes
- 0.42
- Net Income
- 0.31
- Diluted Normalized EPS
- 0.26
- Period
- 2024-03-31
- Total Assets
- 52.74
- Total Liabilities
- 2.06
- Total Equity
- 50.68
- Tangible Book Valueper Share Common Eq
- 36.56
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -7.08
- Cashfrom Investing Activities
- -0.55
- Cashfrom Financing Activities
- 20.36
- Net Changein Cash
- 12.73
- Period
- 2023-12-31
- Total Revenue
- 6.61
- Selling/ General/ Admin Expenses Total
- 0.06
- Depreciation/ Amortization
- 0.16
- Other Operating Expenses Total
- 0.14
- Total Operating Expense
- 6.31
- Operating Income
- 0.3
- Net Income Before Taxes
- 0.29
- Net Income
- 0.24
- Diluted Normalized EPS
- 0.24
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Eiko Lifesciences Technical
Moving Average
SMA
- 5 Day51.04
- 10 Day50.14
- 20 Day50.75
- 50 Day51.64
- 100 Day53.99
- 300 Day57.6
Eiko Lifesciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Shree Hari Chemicals Export
- 155.7
- -1
- -0.64
- 173.9
- 65.65
- 68.39
- Aeonx Digital Technology
- 164.5
- -5.3
- -3.12
- 323.3
- 98.65
- 75.39
- Eiko Lifesciences
- 50
- -2.09
- -4.01
- 74.88
- 42
- 62.1
- Iel
- 5.15
- 0.04
- 0.78
- 7.1
- 3.36
- 66.37
- Dipna Pharmachem
- 25.3
- -0.47
- -1.82
- 26.31
- 6.4
- 59.68
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Shree Hari Chemicals Export
- 31.05
- 3.44
- -11.18
- -4.09
- Aeonx Digital Technology
- 39.04
- 1.57
- 1.14
- 1.12
- Eiko Lifesciences
- 34.97
- 1.22
- 3.39
- 4.25
- Iel
- 88.25
- 18.52
- 39.65
- 9.47
- Dipna Pharmachem
- 28.66
- 1.65
- -
- -
Eiko Lifesciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-May-25
- Audited Results
- 12-Feb-25
- Quarterly Results
- 25-Nov-24
- Rights issue of Equity Shares
- 19-Oct-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 13-May-24
- Audited Results
- 08-Feb-24
- Quarterly Results
- 14-Dec-23
- Others
- 08-Nov-23
- Quarterly Results
- 11-Jul-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 28-Sept-24
- 16-Sept-24
- AGM
- 23-Sept-23
- 30-Aug-23
- AGM
- 06-Mar-23
- 31-Jan-23
- POM
- 31-Mar-21
- 10-Mar-21
- EGM
- -
- 14-Dec-23
- Others



- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 31-Jan-23
- 07-Jul-23
- 07-Jul-23
- 2:3
- 10
- 35
- Rights issue of equity shares of Rs. 10/- in the ratio of 2:3 @ premium of Rs. 35/-.